Modality
Degrader
MOA
PRMT5i
Target
WRN
Pathway
DDR
Crohn'sBladder Ca
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Feb 2028
Phase 1Current
NCT06654011
2,137 pts·Crohn's
2020-02→2028-02·Terminated
2,137 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-191.9y awayPh2 Data· Crohn's
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Termina…
Catalysts
Ph2 Data
2028-02-19 · 1.9y away
Crohn's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06654011 | Phase 1/2 | Crohn's | Terminated | 2137 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C |